Pfizer tries to allay fears over £63bn Astra bid
But Swedish finance minister warns over group's track record
The US pharmaceutical giant Pfizer has hit back at criticism of its £62.5bn bid for its rival AstraZeneca, promising its proposal would speed up the development of new drugs and "bolster innovative science".
The group – which has had two bids rejected by AstraZeneca – has come under attack from politicians, who have raised fears about jobs and the future of Britain's science industry if the largest ever foreign takeover of a UK company goes through.
In an infographic posted on its website, Pfizer said the deal would enable it to "seize new opportunities to expand our global research capabilities and partnerships to better serve patients in need".
The company also quoted the former GlaxoSmithKline chief executive, Sir Richard Sykes, who said that Pfizer had "first-class people doing first-class research".
AstraZeneca has so far rejected Pfizer's advances and on Tuesday Pascal Soriot, the company's chief executive, laid out his defence plan, promising that an independent AstraZeneca will nearly double its annual sales to more than $45bn (£27bn) by 2023, thanks largely to its pipeline of new medicines.
Mr Soriot said that process would be jeopardised by a takeover and added: "I have been through enough mergers to know a company is not a machine. It is a group of people. If you disrupt their work you can really have a negative impact very quickly."
The decision to reject Pfizer's bids has split shareholders, with some of the company's largest investors, including AXA Investment Managers and Schroders, calling for talks even though they believe the price is too low.
Others have backed the company, including Investor AB, which controls 4.1 per cent of AstraZeneca's shares. Sweden's finance minister Anders Borg has even waded into the debate, telling BBC Radio 4's Today programme that his country's experience of pledges from Pfizer had led him to be sceptical of the US firm.
"Our experience shows that their track record is not very convincing and I think one should take these kind of promises not only with a pinch of salt but a sackful of salt," Mr Borg said.
Analysts expect Pfizer to return with another sweetened bid. "We expect the recent flurry of noise coming from Government to provide relatively little of substance and expect a further bid to materialise in the coming weeks," said Savvas Neophytou at Panmure Gordon, who added that AstraZeneca's new projections imply a valuation of as much as £105 a share. "We have set out relatively conservative assumptions which should make a bid of £55 per share easily achievable for Pfizer," the analyst added.
AstraZeneca shares closed down 46.5p at 4,631p.
Meanwhile, at GlaxoSmithKline's annual general meeting yesterday, its chief executive, Sir Andrew Witty, told shareholders that GSK will continue to "watch as bystanders to see what happens with AstraZeneca".
He claimed the company "doesn't believe in big industry-transforming bids" because they can lead to "destructive consequences".
- 1 Venezuela Expo Tattoo 2015: Extreme body art from 'Vampire Woman' to 109mm earlobes
- 2 Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
- 3 Ball pool for adults opens in London
- 4 Game of Thrones season 5 trailer: The first full-length look is here
- 5 Rashida Jones speaks out against male-centric porn saying 'women should have sex and feel good about it'
Mia Khalifa: Pornhub star claims Drake sent her 'cringeworthy' naked photos on Instagram
Boris Johnson claims porn-obsessed Islamic jihadists are 'literally w*****s'
Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
Putin opponent reveals Russian President's daughter's secret identity
Ball pool for adults opens in London
9 reasons Greece's experiment with the radical left is doomed to failure
Have we reached 'peak food'? Shortages loom as global production rates slow
Greece elections: Syriza and EU on collision course after election win for left-wing party
British grandmother Lindsay Sandiford faces execution by firing squad in Indonesia
Liberal Democrat minister defends comments suggesting immigration causes pub closures
King Abdullah dead: We can't afford not to hold Saudi Arabia's royals to account
iJobs Money & Business
£40000 - £50000 per annum: Recruitment Genius: This is an exciting opportunity...
£30000 - £35000 per annum + Benefits: Ashdown Group: Marketing Manager - Marke...
£13000 per annum: Recruitment Genius: This Pension Specialist was established ...
£23000 - £26000 per annum + Benefits: Ashdown Group: Market Research Executive...